Zim Laboratories Limited — Important, 10-01-2025: Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals

ZIM Laboratories Limited and Neuraxpharm have secured Marketing Authorization for their "Buprenorphine Sublingual Film" in Europe, co-developed using ZIM LABS' patented oral thin-film technology. This product targets opioid drug dependence, addressing a European market valued at over USD 355 million annually. The formulation enhances patient safety by minimizing risks of misuse and overdose. This milestone indicates ZIM LABS' commitment to innovative healthcare solutions and positions them well for future commercialization in Europe. Investor sentiment may shift positively as this advancement could open new revenue streams and strengthen their market presence in CNS treatments.